Quantitative risk reduction through epicutaneous immunotherapy (epit): results from the pepites phase iii trial
Peanut allergy prevalence is increasing world-wide and currently no FDA-approved treatment is available. Epicutaneous immunotherapy (EPIT) with Viaskin Peanut (VP250) is being studied in peanut-allergic subjects using a novel single-dose (250 microgram peanut protein) patch. Phase II and III clinical trials have demonstrated a statistically significant benefit of VP250 over placebo through increased eliciting doses on double-blind, placebo-controlled food challenges (DBPCFC). As cross-contamination exposures to peanut through packaged goods are a leading concern and cause of allergic reactions, we aimed to quantify "real world" benefits of EPIT in the pediatric (4-11 years old) peanut-allergic population enrolled in a VP250 Phase III trial.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: B. Remington, T. Krone, S. Koppelman Tags: A302 Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Clinical Trials | Immunotherapy | Peanuts | Pediatrics | Statistics